

Amendments to the Specification

1. On page 1, amend the title of the application as follows:

~~NOVEL~~ CAPSULE FORMULATIONS OF ETOPOSIDE FOR ORAL USE

2. On page 12, amend the paragraph numbered [0057] as follows:

[0057] The present invention also includes methods of preparation of self-microemulsifying formulations of Etoposide. A method of manufacturing a Self-microemulsifying composition of Etoposide with Etoposide ranging from 25 mg to 100 mg/unit dose comprises (i) dissolving Etoposide in Solvent, and cosolvent; (ii) combining the solution of (i) with the lipid, surfactant and ~~stabilizer or~~ stabilizer, or both, and (iii) filling into a pharmaceutically acceptable capsule shell.

3. On page 22, amend the paragraph numbered [0091] as follows:

[0091] e) The self-microemulsifying composition of Etoposide shall comply with the following dissolution specification through its shelf life.

Dissolution condition	% Release in 15 minutes	% Release in 30 minutes
Water at 37°C and at 50 rpm in USP-Type-II apparatus	Not less than 50%	Not less than 75%
<del>PH</del> pH 4.5 USP- acetate buffer at 37°C and at 50 rpm in USP-Type-II apparatus	Not less than 50%	Not less than 85%

4. On page 23, delete the paragraph numbered [0095].

5. On page 23, amend the paragraph numbered [0096] as follows:

[0096] ~~¶~~ f) Because the self-microemulsifying composition of Etoposide in capsule dosage form forms a stable microemulsion upon dilution with Water, or 0.1 N HCl, or pH-4.5 USP-Buffer, or Simulated gastric fluid, or Simulated intestinal fluid, it would result in increase in bioavailability.